{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:56:37Z","timestamp":1792245397025,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtcvs.2025.09.017","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:04:25Z","timestamp":1758344665000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"171","author":[{"given":"David R.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apar Kishor","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Bodla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Batig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Lyfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtcvs.2025.09.017_bib1","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.cllc.2015.12.013","article-title":"Risk factors for local and distant recurrence after surgical treatment in patients with non\u2013small-cell lung cancer","volume":"17","author":"Dziedzic","year":"2016","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.jtcvs.2025.09.017_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jtho.2018.10.002","article-title":"Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010","volume":"14","author":"Okami","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jtcvs.2025.09.017_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000320","article-title":"Lungscape: resected non\u2013small-cell lung cancer outcome by clinical and pathological parameters","volume":"9","author":"Peters","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.jtcvs.2025.09.017_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non\u2013small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jtcvs.2025.09.017_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtcvs.2024.05.009","article-title":"High-risk features associated with recurrence in stage I lung adenocarcinoma","volume":"169","author":"Fick","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7957","key":"10.1016\/j.jtcvs.2025.09.017_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.jtcvs.2025.09.017_bib9","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non\u2013small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jtcvs.2025.09.017_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2024.07.002","article-title":"Clinical utility of tumor-na\u00efve presurgical circulating tumor DNA detection in early-stage NSCLC","volume":"19","author":"Hong","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"10308","key":"10.1016\/j.jtcvs.2025.09.017_bib11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non\u2013small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jtcvs.2025.09.017_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtcvs.2025.09.017_bib13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non\u2013small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jtcvs.2025.09.017_bib14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtcvs.2025.09.017_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtcvs.2025.09.017_bib16","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.jtcvs.2025.09.017_bib18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtcvs.2025.09.017_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtcvs.2025.09.017_bib20","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jtho.2023.09.043","article-title":"Datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced\/mNSCLC: initial results from phase 1b TROPION-Lung04","volume":"18","author":"Papadopoulos","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtcvs.2025.09.017_bib21","article-title":"8O first-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced or metastatic non\u2013small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohorts 2 and 4)","volume":"10","author":"Cuppens","year":"2025","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"10.1016\/j.jtcvs.2025.09.017_bib22","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","article-title":"First-line datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non\u2013small cell lung cancer: results from TROPION-Lung04 (cohort 5)","volume":"43","author":"Waqar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jtcvs.2025.09.017_bib23","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1200\/JCO.2024.42.16_suppl.8617","article-title":"Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non\u2013small cell lung cancer (aNSCLC): subgroup analysis from TROPION-Lung02","volume":"42","author":"Levy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jtcvs.2025.09.017_bib24","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","article-title":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non\u2013small cell lung cancer (aNSCLC)","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtcvs.2025.09.017_bib25","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non\u2013small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jtcvs.2025.09.017_bib26","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jtcvs.2025.09.017_bib27","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","article-title":"COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade","volume":"70","author":"Hansen","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jtcvs.2025.09.017_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jtcvs.2025.09.017_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.jtcvs.2025.09.017_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1471442","article-title":"Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans","volume":"7","author":"Fellermeier-Kopf","year":"2018","journal-title":"Oncoimmunology"},{"issue":"suppl 2","key":"10.1016\/j.jtcvs.2025.09.017_bib31","article-title":"469 preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jtcvs.2025.09.017_bib32","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtho.2024.09.061","article-title":"Efficacy and safety of rilvegostomig, an anti-PD-1\/TIGIT bispecific, for CPI-na\u00efve metastatic NSCLC with PD-L1 1-49% or \u226550%","volume":"19","author":"Hiltermann","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.jtcvs.2025.09.017_bib33","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"7802","key":"10.1016\/j.jtcvs.2025.09.017_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.09.017_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2025.09.017_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102791","article-title":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non\u2013small cell lung cancer","volume":"129","author":"Marinello","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtcvs.2025.09.017_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115237","article-title":"Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non\u2013small cell lung cancer","volume":"217","author":"Hong","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.09.017_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3904\/kjim.2020.011","article-title":"Clinical efficacy of adjuvant chemotherapy in stage IB (<4 cm) non\u2013small cell lung cancer patients with high-risk factors","volume":"37","author":"Choi","year":"2022","journal-title":"Korean J Intern Med"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522325007834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522325007834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:02:22Z","timestamp":1772100142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522325007834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022522325007834"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2025.09.017","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2025.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}]}}